Top Biotech Gainers: DERM Advances On Emrosi Growth, IOVA Revenue Climbs 66%, CAI Raises Guidance

Caris Life Sciences (NASDAQ: CAI) published a study in npj Precision Oncology on an AI tool for pancreatic cancer treatment. The tool, part of the Caris Molecular Tumor Board Report, predicts patient outcomes for two treatments, with median survival of 16 months for FOLFIRINOX vs. 9.9 months for gemcitabine plus nab-paclitaxel. The company's MI Cancer Seek test, FDA-approved in November 2024, includes this tool.

Amylyx Pharmaceuticals (AMLX) surged 63% after reporting positive Phase 3 trial results for avexitide, with Stifel doubling its price target to $45. Iovance Biotherapeutics (IOVA) hit a 52-week high, driven by Q2 earnings and a price target increase from Mizuho. ONEOK (OKE) reached a 52-week high following strong Q2 earnings, raised 2026 guidance, and a new supply deal, with Morgan Stanley raising its target to $105.

IOVA, AMLX, and COP stocks reached 52-week highs. IOVA rose 12% after strong Q2 results and analyst updates, AMLX gained over 2% on positive trial results and a $500M capital raise, and COP increased 3% following strong Q2 earnings and a price target raise. Each company saw improved investor and retail sentiment.

Iovance Biotherapeutics (IOVA) reported early clinical trial results showing lifileucel, its tumor-infiltrating lymphocyte therapy, achieved tumor responses in half of six evaluable patients with advanced soft tissue sarcomas. The company plans a registrational trial and FDA consultation for expedited review. IOVA stock rose over 5% in premarket trading. Q4 revenue was $87M, up 30% YoY, with a 50% gross margin. IOVA stock has fallen 47% over the past year.

Iovance Biotherapeutics (IOVA) surged 12% to a 52-week high after reporting Q2 revenue of $99.3M and a UBS price target raise. Amylyx Pharmaceuticals (AMLX) rose 2% on positive Phase 3 trial results and a $500M offering. ConocoPhillips (COP) gained 3% after strong Q2 earnings and a Morgan Stanley price target increase.

Iovance Biotherapeutics (IOVA) reported Q2 revenue of $99.313M, beating estimates of $87.832M. The company's stock hit a 52-week high, up over 200% year-to-date. Amtagvi, its approved therapy, drove most of the revenue. The company reaffirmed its 2026 sales guidance of $350M to $370M. Analysts adjusted price targets, with UBS raising its target to $7 and Mizuho to $11.